1 / 65

Overview of the 2013 AACE Comprehensive Diabetes Management Algorithm

Overview of the 2013 AACE Comprehensive Diabetes Management Algorithm. Trends in Treatment of T2D-Associated Hyperglycemia. AACE/ACE Diabetes Algorithm for Glycemic Control (2009). Principles of the 2009 AACE/ACE and 2013 AACE Algorithms for Glycemic Control.

waldo
Download Presentation

Overview of the 2013 AACE Comprehensive Diabetes Management Algorithm

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Overview of the 2013 AACE Comprehensive Diabetes Management Algorithm

  2. Trends in Treatment of T2D-Associated Hyperglycemia

  3. AACE/ACE Diabetes Algorithm for Glycemic Control (2009)

  4. Principles of the 2009 AACE/ACE and 2013 AACE Algorithms for Glycemic Control

  5. Comprehensive Approach to Managing T2D

  6. 2013 AACE Comprehensive Diabetes Management Algorithm

  7. Complications-Centric Model for Care of the Overweight/Obese Patient

  8. Prediabetes Algorithm

  9. CVD Risk Factor Modifications Algorithm: Dyslipidemia

  10. CVD Risk Factor Modifications Algorithm: Hypertension

  11. Goals for Glycemic Control

  12. FDA-Approved Pharmacologic Options for Hyperglycemia: Insulin

  13. FDA-Approved Pharmacologic Options for Hyperglycemia: Oral Medications

  14. FDA-Approved Pharmacologic Options for Hyperglycemia: Noninsulin Injectable Agents

  15. Profiles of Antidiabetic Medications

  16. Glycemic Control Algorithm

  17. Algorithm for Adding/Intensifying Insulin

  18. Summary: Comprehensive Care for T2D

  19. Summary: Comprehensive Care for T2D (cont)

  20. 2012 ADA/EASD Position Statement: A Patient-Centered Approach to Managing Hyperglycemia

  21. Did We Really Need Another Guideline?

  22. Impact of Intensive Therapy for Diabetes: Summary of Major Clinical Trials

  23. Main Pathophysiologic Defects in T2D

  24. “We Need Minimally Disruptive Medicine”

  25. Approach to Management of Hyperglycemia

  26. Metformin

  27. Dual and Triple Therapy

  28. Other Treatment Recommendations

  29. Sequential Insulin Strategies in T2D After Noninsulin Regimens

  30. Other Considerations

  31. Considerations for Overweight/Obese Patients

  32. Considerations for Sex, Racial/Ethnic, and Genetic Differences

  33. Considerations for CAD

  34. Considerations for Renal Disease

  35. Considerations for Liver Dysfunction

  36. Summary of Key Points

  37. Incorporating GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Into Clinical Practice

  38. Patient-Centered Care

  39. When Are GLP-1 RAs Indicated?

  40. GLP-1 RAs as Add-on to Metformin

  41. Addition of Insulin to GLP-1 RA and Metformin

  42. GLP-1 RAs vs Insulin Therapy in Patients Suboptimally Uncontrolled

  43. Weight Effect: GLP-1 RAs vs Insulin*

  44. Safety: Nausea

  45. Safety: Pancreatitis

  46. Safety: MTC Risk

  47. Safety: MTC Risk (cont)

  48. Safety: Renal Impairment

  49. Safety: Renal Impairment (cont)

  50. Thank you for participatingin this activity.

More Related